D I Marks - Concepedia

Author

D I Marks

Medical College of Wisconsin ORCID

Also Known As

D I Marks, D Marks, D. I. MARKS, D. I. Marks, D. MARKS, D. Marks, D.I. Marks, Dan Marks, David I. Marks, Devon Marks

Publications

Citations

H-Index

Concepts

All Affiliations

Medical College of Wisconsin Bristol Royal Hospital for Children University Hospitals Cleveland Medical Center University College London Imperial College London

About

D I Marks is an author at Medical College of Wisconsin specializing in medicine, transplantation, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	31	2K
2	Blood Transplantation	14	16	1K
3	Health Sciences	12	12	764
4	Allergy	1	1	49
5	Biochemistry	1	1	35

D I Marks

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant Mary Eapen, Sergio Giralt, Mary M. Horowitz, Bone Marrow Transplantation TransplantationHematologyChronic Leukemia RelapsingGraft SurvivalSecond Transplant	2004	219
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation D I Marks Blood	2002	213
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies Richard F. Olsson, Brent R. Logan, Sonali Chaudhury, Leukemia Radiation OncologyTransplantationMarrow TransplantationStem Cell TransplantationImmunology	2015	138
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease Veronika Bachanová, D I Marks, M-J Zhang, Leukemia TransplantationOncologySimilar SurvivalImmunologyTransplantation Medicine	2013	134
Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR) HM Lazarus, FR Loberiza, M-J Zhang, Bone Marrow Transplantation TransplantationMarrow TransplantationMarrow Transplant RegistryStem Cell TransplantationTransplantation Medicine	2001	116
Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial Bijendra Patel, Amy A. Kirkwood, Aditi Dey, Leukemia	2016	113
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant Bronwen E. Shaw, G J Mufti, Stephen Mackinnon, Bone Marrow Transplantation Transplant RejectionTransplantationReduced-intensity ConditioningMedicineSecond Allogeneic Transplants	2008	111
The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study Sylvia Feyler, H. Miles Prince, Rachel Pearce, Bone Marrow Transplantation Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationAbmtrr Study	2007	101
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis H. Jean Khoury, Muskan Kukreja, J M Goldman, Bone Marrow Transplantation Prognostic FactorsTransplantationMedicineStem Cell TransplantationHematology	2011	94
The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis Kirsten M. Williams, Kwang Woo Ahn, M Chen, Bone Marrow Transplantation Pneumocystis Jiroveci PneumoniaTransplantation MedicineTransplant SurgeryHematopoietic Cell TransplantationCibmtr Analysis	2016	94

Page 1